Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Valerio Therapeutics
Acquired Company
eTheRNA
North Brabant
AntwerpenBiotechnologyHealth CareTherapeuticsManufacturingBiotechnologyTherapeuticsDescription
On October 12, 2026, Valerio Therapeutics announced the completion of its acquisition of 100% of Etherna Immunotherapies NV. This two-stage transaction was finalized after the settlement of shares issued in exchange for Etherna securities. Valerio aims to leverage Etherna's expertise in RNA therapy to enhance targeted treatment capabilities. The acquisition marks a significant milestone in Valerio's strategy to accelerate RNA therapeutics development.
Fundz sees it the moment Valerio Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired eTheRNA?
eTheRNA was acquired by Valerio Therapeutics, based in North Brabant. The deal was reported on October 12, 2026. Valerio Therapeutics is a biotechnology company focused on RNA therapeutics. The company specializes in developing innovative therapies utilizing nucleic acid chemistry. Valerio Therapeutics is privately held and operates in Biotechnology.
When did Valerio Therapeutics acquire eTheRNA?
Valerio Therapeutics's acquisition of eTheRNA was reported on October 12, 2026. On October 12, 2026, Valerio Therapeutics announced the completion of its acquisition of 100% of Etherna Immunotherapies NV. This two-stage transaction was finalized after the settlement of shares issued in exchange for Etherna securities. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does eTheRNA do?
It is privately held, operating in Manufacturing, and is based in Antwerpen.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.